A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses.

ABSTRACT:

Background

We explored the safety and efficacy of ablative doses of stereotactic body radiation therapy (SBRT) for unresectable pancreatic cancer.

Methods

This phase I/II trial included patients with unresectable pancreatic cancer previously treated with any number of cycles of induction chemotherapy. Patients were enrolled according to a 3+3 dose escalation design at 10, 12.5, and 15 Gy ×3, with subsequent patients at the maximally tolerated dose (MTD). Treatment was delivered to gross tumor delineated with MRI fusion using image-guidance to fiducial markers. Dose-limiting toxicity (DLT) was defined as grade 3+ toxicity within 30 days. Secondary endpoints included late gastrointestinal (GI) toxicity, freedom from local failure (FFLF), and survival.

Results

Fifteen pa

SUBMITTER: Liauw SL 

PROVIDER: S-EPMC7807259 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature